<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03427411</url>
  </required_header>
  <id_info>
    <org_study_id>180056</org_study_id>
    <secondary_id>18-C-0056</secondary_id>
    <nct_id>NCT03427411</nct_id>
  </id_info>
  <brief_title>M7824 in Subjects With HPV Associated Malignancies</brief_title>
  <official_title>Phase II Trial of M7824 in Subjects With HPV Associated Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      In the United States, each year there are more than 30,000 cases of human papillomavirus&#xD;
      (HPV) associated cancers. Some of these cancers are often incurable and are not improved by&#xD;
      standard therapies. Researchers want to see if a new drug M7824, which targets and blocks a&#xD;
      pathway that prevents the immune system from effectively fighting the cancer can shrink&#xD;
      tumors in people with some HPV cancers.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To see if the drug M7824 causes tumors to shrink.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Adults age 18 and older who have a cancer associated with HPV infection.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened with medical history and physical exam. They will review their&#xD;
      symptoms and how they perform normal activities. They will have body scans. They will give&#xD;
      blood and urine samples. They will have a sample of their tumor tissue taken if one is not&#xD;
      available.&#xD;
&#xD;
      Participants will have an electrocardiogram to evaluate their heart. Then they will get the&#xD;
      study drug through a thin tube in an arm vein.&#xD;
&#xD;
      Participants will get the drug every 2 weeks for 26 times (1 year). This is 1 course.&#xD;
&#xD;
      After the course, participants will be monitored but will not take the study drug. If their&#xD;
      condition gets worse, they will start another course with the drug. This process can be&#xD;
      repeated as many times as needed.&#xD;
&#xD;
      Treatment will stop if the participant has bad side effects or the drug stops working.&#xD;
&#xD;
      Throughout the study, participants will repeat some or all the screening tests.&#xD;
&#xD;
      After participants stop taking the drug, they will have a follow-up visit and repeat some&#xD;
      screening tests. They will get periodic follow-up phone calls.&#xD;
&#xD;
      ...&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  Metastatic or refractory/recurrent HPV associated malignancies (cervical, anal,&#xD;
           oropharyngeal cancers etc.) are often incurable and poorly palliated by standard&#xD;
           therapies.&#xD;
&#xD;
             -  TGF R1 pathway signaling and overexpression are significantly associated with HPV+&#xD;
                cancers.&#xD;
&#xD;
             -  PD-1 inhibitors have produced a 12-20% response rate for these diseases&#xD;
&#xD;
             -  M7824 is a novel bifunctional fusion protein composed of monoclonal antibodies&#xD;
                against human PD- L1 and soluble extracellular domain of human TGF- receptor II&#xD;
                (TGF- RII), which functions as a TGF- &quot;trap.&quot;&#xD;
&#xD;
             -  Early data from a small cohort of patients with HPV associated malignancies in a&#xD;
                phase I trial of M7824 has shown promising activity (NCT02517398). As of May 30,&#xD;
                2017, 4 of 9 patients (44%) with HPV associated malignancies have had preliminary&#xD;
                evidence of clinical benefit including:&#xD;
&#xD;
        -  Patient with metastatic cervical cancer with a 25% reduction in her disease at 3 months&#xD;
&#xD;
        -  Patient with metastatic P16+ head and neck cancer with an unconfirmed partial response&#xD;
           (PR) at 6 weeks&#xD;
&#xD;
        -  Patient with metastatic anal cancer with a durable PR ongoing 9 months after starting&#xD;
           treatment&#xD;
&#xD;
        -  Patient with metastatic cervical cancer with a durable complete response (CR) ongoing 15&#xD;
           months after starting treatment.&#xD;
&#xD;
        -  Notably, the P16+ head and neck cancer patient with unconfirmed PR, anal cancer patient&#xD;
           with durable PR and cervical cancer patient with durable CR all have HPV+ disease.&#xD;
&#xD;
             -  Immune related adverse events with M7824 in the phase I trial to date have been on&#xD;
                par with other PD-1/PD-L1 inhibitors, suggesting a manageable safety profile.&#xD;
&#xD;
             -  EMD Serono has an ongoing expansion cohort evaluating M7824 in patients with HNSCC&#xD;
                as well as in cervical cancer excluding neuroendocrine cervical cancer.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      -To determine the objective response rate (ORR) according to the Response Evaluation Criteria&#xD;
      in Solid Tumors (RECIST 1.1) in subjects with recurrent or metastatic HPV associated&#xD;
      malignancies.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Age greater than or equal to 18 years old&#xD;
&#xD;
        -  Subjects with cytologically or histologically confirmed locally advanced or metastatic&#xD;
           HPV&#xD;
&#xD;
      associated malignancies including:&#xD;
&#xD;
        -  Non-Neuroendocrine Cervical cancers&#xD;
&#xD;
        -  P16+ Oropharyngeal cancers&#xD;
&#xD;
        -  Anal cancers&#xD;
&#xD;
        -  Vulvar, vaginal, penile, squamous cell rectal and neuroendocrine cervical cancers&#xD;
&#xD;
        -  Other locally advanced or metastatic solid tumors (e.g. lung, esophagus) that are known&#xD;
           HPV+&#xD;
&#xD;
             -  Subjects must have measurable disease.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      -This is a Phase II trial of M7824 in patients with recurrent or metastatic HPV associated&#xD;
&#xD;
      malignancies.&#xD;
&#xD;
      -Patients will be scheduled to receive 1,200 mg of M7824 IV every 2 weeks until off treatment&#xD;
&#xD;
      criteria are met.&#xD;
&#xD;
      -There will be six cohorts: (1) Patients with anal cancer whose disease is na&quot;ve to&#xD;
      checkpoint&#xD;
&#xD;
      inhibition, (2) Patients with non-neuroendocrine cervical cancer na&quot;ve to checkpoint&#xD;
      inhibition,&#xD;
&#xD;
      (3) Patients with P16+ oropharyngeal cancers na&quot;ve to checkpoint inhibition, and (4) Patients&#xD;
      with other rare HPV associated tumors (e.g. squamous cell rectal, vulvar, vaginal, penile&#xD;
      cancer, neuroendocrine cervical) na&quot;ve to checkpoint inhibition, (5) Patients with any HPV&#xD;
      associated cancers whose disease is refractory to checkpoint inhibition. Patients who are&#xD;
      determined to be HPV negative after enrolling will be taken off of their previously assigned&#xD;
      cohort and reassigned to cohort 6 and their slot on their previously assigned cohort will be&#xD;
      replaced.&#xD;
&#xD;
      -Cohorts 1-5 of the trial will be conducted using a Simon two-stage phase II trial design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Every Six weeks</time_frame>
    <description>The percentage of subjects that achieve an objective confirmed complete or partial overall tumor response using RECIST Version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival time (PFS)</measure>
    <time_frame>disease progression or death</time_frame>
    <description>The time from the date of first treatment to the date of disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>6 month</time_frame>
    <description>The percentage of subjects that achieve an objective confirmed complete or partial overall tumor response using RECIST Version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>death</time_frame>
    <description>The time from the date of first treatment to the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability of M7824</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>List of adverse event frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To combine checkpoint inhibitor na(SqrRoot) ve subjects if permitted based on adequate similarity of results in the cohorts 1 and 2</measure>
    <time_frame>one year after last patient enrolls</time_frame>
    <description>The response rates from both cohorts including checkpoint na(SqrRoot) ve subjects, cohort 1 and cohort 2, will be compared with a two-sided Fisher s exact test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the ratio of patients that are hospitalized because of adverse events attributed to disease progression</measure>
    <time_frame>disease progression</time_frame>
    <description>Hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>disease progression</time_frame>
    <description>The time from CR or PR (whichever is first recorded) until the first date that recurrent or PD is objectively documented</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Human Papilloma Virus</condition>
  <condition>Cervical Cancer</condition>
  <condition>Oropharyngeal Cancer</condition>
  <condition>Anal Cancer</condition>
  <condition>Vaginal or Penile Cancer</condition>
  <arm_group>
    <arm_group_label>1/Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M7824 at a flat dose of 1,200 mg IV once every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M7824</intervention_name>
    <description>Flat dose of 1,200 mg of M7824 IV once every 2 weeks</description>
    <arm_group_label>1/Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITIERIA:&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  Ability of subject to understand and the willingness to sign a written informed&#xD;
             consent document.&#xD;
&#xD;
          -  Subjects with cytologically or histologically confirmed locally advanced or metastatic&#xD;
             HPV associated malignancies including:&#xD;
&#xD;
               -  Non-Neuroendocrine Cervical cancers&#xD;
&#xD;
               -  P16+ Oropharyngeal cancers&#xD;
&#xD;
               -  Anal cancers&#xD;
&#xD;
               -  Vulvar, vaginal, penile, squamous cell rectal and neuroendocrine cervical cancers&#xD;
&#xD;
               -  Other locally advanced or metastatic solid tumors (e.g. lung, esophagus) that are&#xD;
                  known HPV+&#xD;
&#xD;
          -  Patients must have disease that is not amenable to potentially curative resection&#xD;
&#xD;
          -  Subjects must have measurable disease&#xD;
&#xD;
          -  ECOG performance status less than or equal to 2&#xD;
&#xD;
          -  Adequate hematologic function at screening, as follows:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) greater than or equal to 1 x 109/L&#xD;
&#xD;
               -  Hemoglobin greater than or equal to 9 g/dL&#xD;
&#xD;
               -  Platelets greater than or equal to 75,000/microliter.&#xD;
&#xD;
          -  Adequate renal and hepatic function at screening, as follows:&#xD;
&#xD;
               -  Serum creatinine less than or equal to 1.5 x upper limit of normal (ULN) OR&#xD;
                  creatinine clearance (CrCl) greater than or equal to 40 mL/min per institutional&#xD;
                  standard&#xD;
&#xD;
               -  Bilirubin less than or equal to 1.5 x ULN OR in subjects with Gilbert's syndrome,&#xD;
                  a total bilirubin less than or equal to 3.0 x ULN&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or&#xD;
                  equal to 2.5 x ULN, unless liver metastases are present, then values must be less&#xD;
                  than or equal to 3 x ULN)&#xD;
&#xD;
          -  The effects of M7824 on the developing human fetus are unknown; thus, women of&#xD;
             childbearing potential and men must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control; abstinence) prior to study entry, for the duration of&#xD;
             study participation and up to 60 days after the last dose of the drug. Should a woman&#xD;
             become pregnant or suspect she is pregnant while she or her partner is participating&#xD;
             in this study,she should inform her treating physician immediately.&#xD;
&#xD;
          -  Patients serologically positive for HIV, Hep B, Hep C are eligible as long as the&#xD;
             viral loads are undetectable by quantitative PCR. HIV positive patients must have CD4&#xD;
             count greater than or equal to 300 cells per cubic millimeter at enrollment, be on&#xD;
             stable antiretroviral therapy and have no reported opportunistic infections within 12&#xD;
             months prior to enrollment.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        -Pregnant women are excluded from this study because this drug has not been tested in&#xD;
        pregnant women and there is potential for teratogenic or abortifacient effects. Because&#xD;
        there is an unknown but potential risk for adverse events in nursing infants secondary to&#xD;
&#xD;
        treatment of the mother with M7824, breastfeeding should be discontinued if the mother is&#xD;
        treated with M7824.&#xD;
&#xD;
          -  Patients with prior investigational drug, chemotherapy, immunotherapy or any prior&#xD;
             radiotherapy (except for palliative bone directed therapy) within the past 28 days&#xD;
             prior to the first drug administration except if the investigator has assessed that&#xD;
             all residual treatment-related toxicities have resolved or are minimal and feel the&#xD;
             patient is otherwise suitable for enrollment. Patients may continue adjuvant hormonal&#xD;
             therapy in the setting of a definitively treated cancer (e.g. breast).&#xD;
&#xD;
          -  Major surgery within 28 days prior to the first drug administration (minimally&#xD;
             invasive procedures such as diagnostic biopsies are permitted).&#xD;
&#xD;
          -  Known intolerance to or life threatening side effects resulting from prior checkpoint&#xD;
             inhibitor therapy.&#xD;
&#xD;
          -  Known active brain or central nervous system metastasis (less than 1 month out from&#xD;
             definitive radiotherapy or surgery), seizures requiring anticonvulsant treatment (&lt;3&#xD;
             months) or clinically significant cerebrovascular accident (&lt;3 months). In order to be&#xD;
             eligible patients must have repeat CNS imaging at least two months after definitive&#xD;
             treatment showing stable CNS disease. Patients with evidence of intratumoral or&#xD;
             peritumoral hemorrhage on baseline imaging are also excluded unless the hemorrhage is&#xD;
             grade less than or equal to 1 and has been shown to be stable on two consecutive&#xD;
             imaging scans.&#xD;
&#xD;
          -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory&#xD;
             agent with exception of:&#xD;
&#xD;
               -  diabetes type I, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid&#xD;
                  disease or other mild autoimmune disorders not requiring immunosuppressive&#xD;
                  treatment;&#xD;
&#xD;
               -  Subjects requiring hormone replacement with corticosteroids are eligible if the&#xD;
                  steroids are administered only for the purpose of hormonal replacement and at&#xD;
                  doses less than or equal to 10 mg of prednisone or equivalent per day;&#xD;
&#xD;
               -  Administration of steroids for other conditions through a route known to result&#xD;
                  in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation)&#xD;
                  is acceptable;&#xD;
&#xD;
               -  Subjects on systemic intravenous or oral corticosteroid therapy with the&#xD;
                  exception of physiologic doses of corticosteroids (less than or equal to the&#xD;
                  equivalent of prednisone 10 mg/day) or other immunosuppressives such as&#xD;
                  azathioprine or cyclosporin A are excluded on the basis of potential immune&#xD;
                  suppression. For these subjects these excluded treatments must be discontinued at&#xD;
                  least 1 weeks prior to enrollment for recent short course use (less than or equal&#xD;
                  to 14 days) or discontinued at least 4 weeks prior to enrollment for long term&#xD;
                  use (&gt;14 days). In addition, the use of corticosteroids as premedication for&#xD;
                  contrastenhanced studies is allowed prior to enrollment and on study.&#xD;
&#xD;
          -  Subjects with a history of serious intercurrent chronic or acute illness, such as&#xD;
             cardiac or pulmonary disease, hepatic disease, bleeding diathesis or recent (within 3&#xD;
             months) clinically significant bleeding events, or other illness considered by the&#xD;
             Investigator as high risk for investigational drug treatment.&#xD;
&#xD;
          -  History of non-HPV associated second malignancy within 3 years of enrollment except&#xD;
             localized malignancy which has been adequately treated or malignancy which does not&#xD;
             require active systemic treatment (e.g. low risk CLL).&#xD;
&#xD;
          -  Known severe hypersensitivity reactions to monoclonal antibodies (Grade greater than&#xD;
             or equal to 3 NCI CTCAE v4.03)&#xD;
&#xD;
          -  Receipt of any organ transplantation requiring ongoing immunosuppression.&#xD;
&#xD;
          -  Patients with vulvar cancer originating from differentiated vulvar intraepithelial&#xD;
             neoplasia (d-VIN), as opposed to vulvar intraepithelial neoplasia of usual type, are&#xD;
             excluded. Vulvar squamous cell carcinoma originating from differentiated VIN (d-VIN)&#xD;
             is HPV negative; however, rare cases of HPV positive d-VIN can occur. Patients are not&#xD;
             excluded if their tumor has tested positive for HPV or there is no documentation of&#xD;
             prior VIN type.&#xD;
&#xD;
          -  Patients with known HPV negative malignancies based on comprehensive laboratory&#xD;
             testing (e.g. PCR based assay evaluating for HPV 16, 18, 31, 33, 35, 39, 51, 52, 56,&#xD;
             58, 59, 66, 68). Patients with HPV associated malignancies and unknown HPV status&#xD;
             prior to enrollment are eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julius Y Strauss, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2018-C-0056.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, Razzaghi H, Saraiya M. Human Papillomavirus-Associated Cancers - United States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2016 Jul 8;65(26):661-6. doi: 10.15585/mmwr.mm6526a1.</citation>
    <PMID>27387669</PMID>
  </reference>
  <reference>
    <citation>Levovitz C, Chen D, Ivansson E, Gyllensten U, Finnigan JP, Alshawish S, Zhang W, Schadt EE, Posner MR, Genden EM, Boffetta P, Sikora AG. TGFÎ² receptor 1: an immune susceptibility gene in HPV-associated cancer. Cancer Res. 2014 Dec 1;74(23):6833-44. doi: 10.1158/0008-5472.CAN-14-0602-T. Epub 2014 Oct 1.</citation>
    <PMID>25273091</PMID>
  </reference>
  <reference>
    <citation>Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One. 2015 Jun 26;10(6):e0131403. doi: 10.1371/journal.pone.0131403. eCollection 2015. Review.</citation>
    <PMID>26114883</PMID>
  </reference>
  <verification_date>October 13, 2021</verification_date>
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TGFR1 pathway signaling and overexpression</keyword>
  <keyword>PD-1 inhibitors</keyword>
  <keyword>Manageable Safety Profile</keyword>
  <keyword>Bifunctional Fusion Protein</keyword>
  <keyword>Refractory/Recurrent HPV Associated Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Penile Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

